NewBiologix Launches Proprietary HEK293 Cell Line for the Expression of Viral Vectors Used in Gene Therapy
NewBiologix SA, a technology innovation company focused on addressing gene and cell therapy manufacturing gaps, announced today the launch of NBX-HEK293, the Company’s engineered host HEK293 cell line for the production of recombinant adeno-associated viruses (rAAV) used in gene therapy.
- NewBiologix SA, a technology innovation company focused on addressing gene and cell therapy manufacturing gaps, announced today the launch of NBX-HEK293, the Company’s engineered host HEK293 cell line for the production of recombinant adeno-associated viruses (rAAV) used in gene therapy.
- This novel and commercially available host cell line marks a significant advancement for biopharmaceutical companies dedicated to developing gene therapies.
- NBX-HEK293 consistently outperformed the host polyclonal HEK293 cell line in terms of rAAV production.
- This translates to higher yields and greater reliability, addressing a significant bottleneck currently experienced when producing viral vectors for gene therapies.